Description: Faron Pharmaceuticals Oy is a Finland-based biopharmaceutical company engaged in the biotechnology and medical research industry. The Company develops late stage clinical drugs focusing on acute organ traumas, cancer immunotherapy and vascular damage. Its product pipeline includes Traumakine (FP-1201-lyo), an Acute Respiratory Distress Syndrome (ARDS) treatment that is in phase Three development; and Clevegen (FP-1304), an anti-Clever-1 immunotheraphy tumor targeting candidate that is in pre-clinical stage development.
Home Page: www.faron.com
FARN Technical Analysis
Joukahaisenkatu 6 B
Turku,
20520
Finland
Phone:
358 2469 5151
Officers
| Name | Title |
|---|---|
| Dr. Juho Markku Jalkanen M.D., MSc, Ph.D. | Chief Operating Officer |
| Dr. Markku Tapani Jalkanen Ph.D. | Founder, CEO & Exec. Director |
| Mr. Toni Hänninen | Chief Financial Officer |
| Dr. Maija Hollmen Ph.D. | Chief Scientific Officer |
| Eric Van Zanten | Head of Communications |
| Dr. Juhana Heinonen | Chief Commercial Officer |
| Dr. Marie-Louise Fjallskog M.D., Ph.D. | Chief Medical Officer |
| Dr. Ilse Piippo | Regulatory Consultant |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 43.2701 |
| Price-to-Sales TTM: | 16.209 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 37 |